In January, 2017, the Federal Court of Appeal (FCA) upheld the validity and the infringement of AstraZeneca's omeprazole formulation patent by Apotex in Apotex Inc v AstraZeneca Canada Inc, 2017 FCA 9.
Federal Court of Appeal Affirms Validity and Infringement of AstraZeneca's Omeprazole Formulation Patent but Amends Application of 6 - Year Limitation Period